
Sign up to save your podcasts
Or


Shareholders of ResMed have been on a rollercoaster ride in the past year. Late last year, after news of the efficacy of Ozempic and other GLP-1 drugs came to light, the ResMed share price dropped as investors grew concerned about the potential impact on ResMed’s business. But since then it has steadily made up lost ground and is now trading at similar levels.
In our latest podcast, IML’s Senior Equity Analyst Bruce Du, gives his perspective.
AI has easily been the hottest topic in investing this year. While IML Portfolio Manager Daniel Moore is excited about AI’s potential, he sounds a reminder that investing in popular themes is “fraught with danger”. Instead of buying AI-themed market darlings which are now trading at heady valuations, he suggests long-term investors should consider companies which are investing heavily in AI, and are likely to be beneficiaries of it, but haven’t yet seen their share prices appreciate significantly.
What are the future economic implications of Australia’s heavy reliance on mining, agriculture, tourism and international education?
In this episode of Navigating the Noise, join Louise Watson, Head of Natixis Investment Managers Australia & New Zealand, for part two of her conversation with demographer Simon Kuestenmacher, this time to discuss Australia’s business model, now and in the future.
Simon and Louise explore:
IML's Daniel Moore discusses key stock movements and the future outlook of the large cap fund.
Find out how the small-mid cap funds performed during the March quarter and why Simon Conn believes many small caps are still undervalued.
In the inaugural episode of Navigating the Noise, Louise Watson, Head of Natixis Investment Managers Australia & New Zealand, joins demographer Simon Kuestenmacher to explore Australia’s burgeoning population and the potential ramifications this will have for our society, economy and investment decisions.
Simon unpacks key data on:
From the publisher's feed